1. Home
  2. SCLX vs HBIO Comparison

SCLX vs HBIO Comparison

Compare SCLX & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scilex Holding Company

SCLX

Scilex Holding Company

N/A

Current Price

$2.06

Market Cap

27.9M

Sector

Health Care

ML Signal

N/A

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

N/A

Current Price

$8.33

Market Cap

26.5M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
SCLX
HBIO
Founded
2011
1901
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
27.9M
26.5M
IPO Year
2020
2000

Fundamental Metrics

Financial Performance
Metric
SCLX
HBIO
Price
$2.06
$8.33
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 40.4K
15.2K
Earning Date
11-13-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
$30,253,000.00
★ $116,176,000.00
Revenue This Year
$118.16
$3.76
Revenue Next Year
$186.31
$5.29
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$2.27
$0.40
52 Week High
$27.00
$8.80

Technical Indicators

Market Signals
Indicator
SCLX
HBIO
Relative Strength Index (RSI) 14.46 57.98
Support Level N/A $7.90
Resistance Level $7.77 N/A
Average True Range (ATR) 0.23 0.36
MACD -0.01 -0.01
Stochastic Oscillator 2.53 56.67

Price Performance

Historical Comparison
SCLX
HBIO

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

Share on Social Networks: